{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:05:49Z","timestamp":1790784349094,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T00:00:00Z","timestamp":1493078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2017,8,15]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Mirvetuximab soravtansine (IMGN853) is an antibody\u2010drug conjugate that selectively targets folate receptor \u03b1 (FR\u03b1). In this phase 1 dose\u2010escalation study, the authors investigated IMGN853 in patients with FR\u03b1\u2010positive solid tumors.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Patients received IMGN853 on day 1 of a 21\u2010day cycle (once every 3 weeks dosing), with cycles repeated until patients experienced dose\u2010limiting toxicity or progression. Dose escalation commenced in single\u2010patient cohorts for the first 4 planned dose levels and then followed a standard 3 + 3 scheme. The primary objectives were to determine the maximum tolerated dose and the recommended phase 2 dose. Secondary objectives were to determine safety and tolerability, to characterize the pharmacokinetic profile, and to describe preliminary clinical activity.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>In total, 44 patients received treatment at doses escalating from 0.15 to 7.0 mg\/kg. No meaningful drug accumulation was observed with the dosing regimen of once every 3 weeks. The most common treatment\u2010related adverse events were fatigue, blurred vision, and diarrhea, the majority of which were grade 1 or 2. The dose\u2010limiting toxicities observed were grade 3 hypophosphatemia (5.0 mg\/kg) and grade 3 punctate keratitis (7.0 mg\/kg). Two patients, both of whom were individuals with epithelial ovarian cancer, achieved confirmed tumor responses according to Response Evaluation Criteria in Solid Tumors 1.1, and each was a partial response.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>IMGN853 demonstrated a manageable safety profile and encouraging preliminary clinical activity, particularly in patients with ovarian cancer. The results establish a recommended phase 2 dosing of 6.0 mg\/kg (based on adjusted ideal body weight) once every 3 weeks. <jats:bold><jats:italic>Cancer<\/jats:italic> 2017<\/jats:bold>. \u00a9 <jats:italic>2017 American Cancer Society<\/jats:italic>. <jats:bold><jats:italic>Cancer<\/jats:italic> 2017;123:3080\u20137.<\/jats:bold> \u00a9 <jats:italic>2017 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.30736","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T15:25:50Z","timestamp":1493133950000},"page":"3080-3087","source":"Crossref","is-referenced-by-count":142,"title":["Phase 1 dose\u2010escalation study of mirvetuximab soravtansine (<scp>IMGN853<\/scp>), a folate receptor \u03b1\u2010targeting antibody\u2010drug conjugate, in patients with solid tumors"],"prefix":"10.1002","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5803-0718","authenticated-orcid":false,"given":"Kathleen N.","family":"Moore","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology University of Oklahoma Health Sciences Center Oklahoma City Oklahoma"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Borghaei","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology Fox Chase Cancer Center Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O'Malley","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology The Ohio State University College of Medicine Columbus Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woondong","family":"Jeong","sequence":"additional","affiliation":[{"name":"Cancer Therapy and Research Center University of Texas Health Science Center San Antonio Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly M.","family":"Seward","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Wayne State University Detroit Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Bauer","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute\/Tennessee Oncology PLLC Nashville Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond P.","family":"Perez","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Kansas Fairway Kansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula A.","family":"Matulonis","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana Farber Cancer Institute Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli L.","family":"Running","sequence":"additional","affiliation":[{"name":"ImmunoGen, Inc. Waltham Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"ImmunoGen, Inc. Waltham Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose F.","family":"Ponte","sequence":"additional","affiliation":[{"name":"ImmunoGen, Inc. Waltham Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Ruiz\u2010Soto","sequence":"additional","affiliation":[{"name":"ImmunoGen, Inc. Waltham Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Birrer","sequence":"additional","affiliation":[{"name":"Gillette Center for Gynecologic Oncology Massachusetts General Hospital Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,4,25]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"2027","article-title":"The relationship between high\u2010dose treatment and combination chemotherapy: the concept of summation dose intensity","volume":"4","author":"Frei E","year":"1998","journal-title":"Clin Cancer Res."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1021\/ar700108g"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2013.805200"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929866521666140804160907"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201307628"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchem.2415"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2004.01.001"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-007-9048-0"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2014.10.002"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv250"},{"key":"e_1_2_8_12_1","first-page":"118","article-title":"Targeting the folate receptor for the treatment of ovarian cancer","volume":"4","author":"Lutz RJ","year":"2015","journal-title":"Transl Cancer Res."},{"key":"e_1_2_8_13_1","first-page":"1424","article-title":"EC\u2010145, a folate\u2010targeted Vinca alkaloid conjugate for the potential treatment of folate receptor\u2010expressing cancers","volume":"11","author":"Dosio F","year":"2010","journal-title":"Curr Opin Investig Drugs."},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2014.909723"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712591003592069"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.2596"},{"key":"e_1_2_8_17_1","unstructured":"Endocye Inc.Merck and Endocyte Announce Independent DSMB Recommends Vintafolide PROCEED Phase 3 Trial Be Stopped for Futility Following Interim Analysis. Endocyte Inc. Available at:http:\/\/investor.endocyte.com\/releasedetail.cfm?ReleaseID=844838. Accessed October 25 2016."},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12044"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1021\/bc900315y"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5b00175"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-1095"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_8_23_1","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1200\/jco.2014.32.15_suppl.5571","article-title":"Relationship of pharmacokinetics (PK), toxicity, and initial evidence of clinical activity with IMGN853, a folate receptor alpha (FRa) targeting antibody drug conjugate in patients (Pts) with epithelial ovarian cancer (EOC) and other FRa\u2010positive solid tumors [abstract]","volume":"32","author":"Moore KN","year":"2014","journal-title":"J Clin Oncol."},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0700"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-014-0180-8"},{"key":"e_1_2_8_26_1","first-page":"15S","article-title":"A phase I study of SAR566658, an anti CA6\u2010antibody drug conjugate (ADC), in patients (Pts) with CA6\u2010positive advanced solid tumors (STs) (NCT01156870) [abstract]","volume":"34","author":"Gomez\u2010Roca CA","year":"2016","journal-title":"J Clin Oncol."},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2015.0064"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines4030014"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.114.009373"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S40947"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-014-9539-8"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.11.020"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980417)79:2<121::AID-IJC4>3.0.CO;2-V"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.9538"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.30736","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.30736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:32:36Z","timestamp":1760297556000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.30736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,25]]},"references-count":33,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2017,8,15]]}},"alternative-id":["10.1002\/cncr.30736"],"URL":"https:\/\/doi.org\/10.1002\/cncr.30736","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,25]]}}}